IP Library Granted Patent US 7,935,800
Granted Patent B2
US 7,935,800 · App. 11/642,815 · Granted May 3, 2011

RNA detection assays

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,800
App. No.
11/642,815
Granted
May 3, 2011
Kind
B2
Abstract

The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5′ nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Claims (28)

1. A method for detecting the presence of a target nucleic acid comprising:

a) forming an invasive cleavage structure, said invasive cleavage structure comprising an RNA target nucleic acid;

b) cleaving said invasive cleavage structure with a cleavage agent comprising an isolated composition comprising the polypeptide of SEQ ID NO:2668 to produce a non-target cleavage product; and

c) detecting the cleavage of said invasive cleavage structure,

wherein said target nucleic acid comprises a first region and a second region, said second region downstream of and contiguous to said first region, and wherein said invasive cleavage structure comprises said target nucleic acid, a first oligonucleotide, and a second oligonucleotide, wherein at least a portion of said first oligonucleotide is completely complementary to said first region of said first target nucleic acid, and wherein said second oligonucleotide comprises a 3′ portion and a 5′ portion, wherein said 5′ portion is completely complementary to said second region of said target nucleic acid.

2. The method of claim 1 , wherein at least said portion of said first oligonucleotide is annealed to said first region of said target nucleic acid and wherein at least said 5′ portion of said second oligonucleotide is annealed to said second region of said target nucleic.

3. The method of claim 2 , wherein said 3′ portion of said second oligonucleotide comprises a 3′ terminal nucleotide not complementary to said target nucleic acid.

4. The method of claim 3 , wherein said 3′ portion of said second oligonucleotide consists of a single nucleotide not complementary to said target nucleic acid.

5. The method of claim 1 , wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence.

6. The method of claim 1 , wherein said detecting the cleavage of said invasive cleavage structure comprises detection of mass.

7. The method of claim 1 , wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence energy transfer.

8. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge.

9. The method of claim 1 , further comprising the steps of forming a second invasive cleavage structure comprising said non-target cleavage product and cleaving said second invasive cleavage structure.

10. The method of claim 1 , wherein said RNA target nucleic acid comprises a cytochrome P450 RNA.

11. The method of claim 1 , wherein said RNA target nucleic acid comprises a cytokine RNA.

12. The method of claim 1 , wherein a portion of said target nucleic acid consisting of said first region and said second region of said target nucleic acid comprises a splice junction.

13. The method of claim 1 , wherein said first region or said second region of said target nucleic acid comprises an exon.

14. The method of claim 1 , wherein said first region or said second region of said target nucleic acid comprises an intron.

15. The method of claim 1 , wherein said RNA target nucleic acid is provided in a cell lysate.

16. The method of claim 1 , wherein said first oligonucleotide is covalently attached to said second oligonucleotide.

17. A method for detecting the presence of two or more target nucleic acid sequences comprising:

a) cleaving two or more invasive cleavage structures with a cleavage agent comprising an isolated composition comprising the polypeptide of SEQ ID NO:2668, each of said two or more invasive cleavage structures comprising an RNA target nucleic acid having a target sequence, wherein each of said invasive cleavage structures comprises a different RNA target sequence; and

b) detecting the cleavage of said invasive cleavage structure.

18. A recombinant nucleic acid composition comprising a nucleic acid encoding the polypeptide of SEQ ID NO:2668.

19. A vector comprising the nucleic acid sequence of claim 18 .

20. A host cell comprising the vector of claim 19 .

21. The composition of claim 18 , wherein said nucleic acid comprises SEQ ID NO:2702.

22. An isolated composition comprising the polypeptide of SEQ ID NO:2668.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →